247 related articles for article (PubMed ID: 25775381)
1. Erythrocytosis associated with hyperthyroidism: a rare case report and clinical study of possible mechanism.
Liu X; Liu J; Fan L; Shi B
Endocr Res; 2015; 40(4):177-80. PubMed ID: 25775381
[TBL] [Abstract][Full Text] [Related]
2. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
3. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
[TBL] [Abstract][Full Text] [Related]
4. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease.
Bogazzi F; Bartalena L; Campomori A; Brogioni S; Traino C; De Martino F; Rossi G; Lippi F; Pinchera A; Martino E
J Clin Endocrinol Metab; 2002 Oct; 87(10):4490-5. PubMed ID: 12364424
[TBL] [Abstract][Full Text] [Related]
5. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism.
Andrade VA; Gross JL; Maia AL
J Clin Endocrinol Metab; 1999 Nov; 84(11):4012-6. PubMed ID: 10566642
[TBL] [Abstract][Full Text] [Related]
6. Response to methimazole in Graves' disease. The European Multicenter Study Group.
Benker G; Vitti P; Kahaly G; Raue F; Tegler L; Hirche H; Reinwein D
Clin Endocrinol (Oxf); 1995 Sep; 43(3):257-63. PubMed ID: 7586593
[TBL] [Abstract][Full Text] [Related]
7. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
8. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.
Takata K; Amino N; Kubota S; Sasaki I; Nishihara E; Kudo T; Ito M; Fukata S; Miyauchi A
Clin Endocrinol (Oxf); 2010 Jun; 72(6):845-50. PubMed ID: 19912243
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
[TBL] [Abstract][Full Text] [Related]
10. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
[TBL] [Abstract][Full Text] [Related]
11. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
Tsai WC; Pei D; Wang TF; Wu DA; Li JC; Wei CL; Lee CH; Chen SP; Kuo SW
Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
[TBL] [Abstract][Full Text] [Related]
12. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
[TBL] [Abstract][Full Text] [Related]
14. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism.
Sato S; Noh JY; Sato S; Suzuki M; Yasuda S; Matsumoto M; Kunii Y; Mukasa K; Sugino K; Ito K; Nagataki S; Taniyama M
Thyroid; 2015 Jan; 25(1):43-50. PubMed ID: 25178068
[TBL] [Abstract][Full Text] [Related]
15. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
[TBL] [Abstract][Full Text] [Related]
16. Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy.
Antonelli A; Ferrari SM; Corrado A; Ferrannini E; Fallahi P
Thyroid; 2013 Nov; 23(11):1461-9. PubMed ID: 23721189
[TBL] [Abstract][Full Text] [Related]
17. Serum insulin-like growth factor-I, insulin-like growth factor binding proteins, and bone mineral content in hyperthyroidism.
Lakatos P; Foldes J; Nagy Z; Takacs I; Speer G; Horvath C; Mohan S; Baylink DJ; Stern PH
Thyroid; 2000 May; 10(5):417-23. PubMed ID: 10884189
[TBL] [Abstract][Full Text] [Related]
18. The Local HIF-2α/EPO Pathway in the Bone Marrow is Associated with Excessive Erythrocytosis and the Increase in Bone Marrow Microvessel Density in Chronic Mountain Sickness.
Su J; Li Z; Cui S; Ji L; Geng H; Chai K; Ma X; Bai Z; Yang Y; Wuren T; Ge RL; Rondina MT
High Alt Med Biol; 2015 Dec; 16(4):318-30. PubMed ID: 26625252
[TBL] [Abstract][Full Text] [Related]
19. Oxidation products and antioxidant markers in plasma of patients with Graves' disease and toxic multinodular goiter: effect of methimazole treatment.
Bednarek J; Wysocki H; Sowinski J
Free Radic Res; 2004 Jun; 38(6):659-64. PubMed ID: 15346657
[TBL] [Abstract][Full Text] [Related]
20. [Effects of methimazole on the evolution of the allergic rhinitis of patients with Graves' disease].
Valencia Zavala MP; Cortinas López L; Sánchez Olivas JA; Sánchez Olivas MA; Montes Montes J; Duarte Díaz RJ; León Oviedo C
Rev Alerg Mex; 2007; 54(3):71-6. PubMed ID: 17849791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
